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Abstract 
Background 
Diagnosis of prion disease from blood samples requires the detection of minute quantities 
of misfolded protein (PrPSc) against a high background of correctly folded material 
(PrPC). Protein Misfolding Cyclic Amplification (PMCA) is a technique which can 
amplify small amounts of seed PrPSc to a level detectable by conventional methods. 
Application of PMCA to the testing of whole blood samples enhances the ability to detect 
PrPSc and allows ante-mortem detection of prion infection and could facilitate blood 
screening. 
 
Study Design and Methods 
The PMCA methodology was used to detect prion infection in blood samples obtained 
from mice experimentally infected with prion disease. Mice were culled at various time 
points throughout the incubation period for disease and subjected to serial PMCA 
(sPMCA). Amplified samples were then analysed by western blotting to confirm the 
presence or absence of infection. 
 
Results 
After sPMCA, blood samples from RML-infected mice showed amplification of PrPSc to 
levels readily detectable by western blotting. Control samples obtained from mice mock 
inoculated with sterile PBS did not yield any amplification products.  
 
Conclusion 
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Serial PMCA performed on small volumes of whole blood gave amplification of PK 
resistant material to a level detectable by standard methods. Discrimination between 
infected and control samples was achieved without the need for processing or 
fractionation of whole blood. The use of whole blood as an analyte circumvents the need 
to identify the optimal blood compartment for analysis and guarantees the totality of 
misfolded PrP will be available for detection. 
 
Keywords: Variant CJD, Prion, PMCA, PrP 
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Introduction 
Prion diseases are fatal neurodegenerative disorders that included bovine spongiform 
encephalopathy (BSE) in cattle, scrapie in sheep and Creutzfeldt-Jakob disease (CJD) in 
humans1,2.  The crucial step in the transmission and propagation of prion diseases, 
according to the protein-only hypothesis3 is the conversion of the host’s normal, cellular 
form of the prion protein (PrPC), via a post-translational process to a protease-resistant, 
aggregated form (PrPSc)4.  Detection of disease-associated PrPSc is the most widely used 
and specific criterion for the diagnosis of prion disease in humans and animals1,2. 
 
Recent studies have shown that significant prion infectivity is present in non-neuronal or 
lymphatic tissues, such as blood and urine 5,6 which suggests the potential risk of prion 
infection via a range of different tissues.  In fact, current evidence suggests that blood 
transfusions may provide an effective route of transmission for prion infection in humans 
as well as animals7-10.  Taken together with the extended length of the pre-clinical period 
of vCJD, transmission of vCJD via transfusion or other iatrogenic means has become an 
issue of public concern.  Therefore a diagnostic test which can be applied to the rapid 
screening of transfusion samples as well as blood products is highly desirable. 
 
However, the diagnostic detection of PrPSc in blood is not a trivial matter.  Very little is 
known about the nature and distribution of infectious material in blood, and what is know 
is largely derived from rodent models not human disease states. Infectivity has been 
detected in buffy coat fractions as well as plasma from rodents,11,12 with as little as 10 
infectious units present in 1ml of whole blood.  As well as the extremely low 
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concentration of disease associated PrPSc there is a very high background of PrPC present 
in white blood cells, red blood cells and platelets.  A combined methodology of 
enrichment and detection of PrPSc by high sensitivity ELISA have shown potential as a 
blood based test for infection (Tattum et al. Submitted). 
 
Further significant increases in the sensitivity of detecting prion infection in blood can be 
achieved by exploiting the ability of prions to replicate in vitro to achieve both 
amplification of abnormal PrP and a decrease in the ratio of background PrPC to PrPSc.  
Several methods have been developed, including those that use recombinant prion 
proteins as a substrate 13,14. However, the highest fidelity and the replication of authentic 
prions are limited to Protein Misfolding Cyclic Amplification (PMCA) in vitro. PMCA is 
a technique developed by Soto and colleagues which allows the amplification of minute 
quantities of PrPSc to levels which can be detected by conventional methods15.  PMCA is 
a cyclical process analogous to PCR where there are periods of seeded conversion of 
PrPC from the substrate homogenate by small amounts of PrPSc interspersed with bursts 
of sonication which disrupt PrP aggregates allowing continued recruitment and 
conversion of PrPC.  The only limiting factor to the level of amplification is the 
exhaustion of the substrate PrPC or other factors necessary for amplification.  To 
overcome this serial PMCA (sPMCA), in which samples after amplification are diluted 
into fresh substrate and subjected to further rounds of PMCA, has been developed16.  
PMCA has been used to detect PrPSc in Buffy coat fractions from rodent blood17,18.  More 
recently PrPSc was amplified from blood leukocyte preparations taken from scrapie 
infected sheep19.  However, the use of buffy coat in the kind of rapid, large-scale blood 
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test required is likely to be unfeasible due the time-consuming nature of the separation of 
blood components.  Also, further processing of buffy coat fractions is required before it 
can be used as a seed in PMCA reactions. Despite buffy coat being shown to contain the 
highest concentration of prions11,12,20-22 the total infectivity partitioned into this fraction is 
only about one third of the total in whole blood.   
 
With this in mind we set out to adapt PMCA to use whole blood as the seed for our 
amplification, as this is the most practical material to use for blood screening and will 
contain the infectivity associated with all fractions.  Substrate homogenates for 
amplification were generated from the brains of transgenic Tg20 mice which overexpress 
PrPC 23.  Here we report the first amplification of proteinase-K resistant PrP (PrPRES) from 
PMCA reactions seeded with prion infected whole blood.  Using a small volume of 
whole blood from RML infected CD1 mice, PrPRES was amplified to a level detectable by 
Western blotting after 4 rounds of serial PMCA.  PrPRES was not observed in control 
normal whole blood after four sPMCA cycles, suggesting that this represents the 
amplification of genuine PrPSc present in the animals blood rather than the de novo 
spontaneous generation of PrPRES that has been reported elsewhere19,24.  The sensitivity of 
the technique allowed the diagnosis of prion infection in late-stage pre-clinical animals 
and represents an important step forward in the simplification of blood-based assays 
utilising prion propagation in vitro. 
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Methods 
Tissues samples 
All procedures were carried out in a microbiological containment level III facility with 
strict adherence to safety protocols. The Rocky Mountain Laboratory (RML) strain of 
prions25, a mouse adapted prion strain isolated by serial passage from an original 
inoculum of sheep scrapie, was used to establish experiment rodent infections. Normal 
brains from the outbred CD1 strain of wild-type mice and transgenic Tg2023 mice, as well 
as brains from CD1 mice which were experimentally infected with the RML scrapie 
prion strain were homogenized in Dulbecco's PBS (DPBS) lacking Ca2+ or Mg2+ ions by 
serial passage through needles of decreasing diameter or the use of tissue grinders 
(Anachem) to give a final concentration of 10% (w/v)26,27. Tissue homogenates were 
stored as aliquots in eppenforf tubes at -80°C.  Preparation of PMCA substrate 
homogenates is detailed below.  Whole normal blood was collected from uninfected CD1 
mice. 
 
Time course of RML infection in CD1 mice 
RML time course of infection was performed by inoculating CD1 mice inter-cortically 
(i.c.) with 30µl 1% (w/v) RML infected brain homogenate made up in PBS.  Groups of 
20 mice were culled at 0, 20, 40, 60, 80, 100, 120, 140 days after infection and animals 
succumbed to disease 148 days post- infection.  Brains and bloods were collected at each 
time point for analysis.  The presence of PrPSc in brain tissue was determined by western 
blotting and infectivity quantified by automated Scrapie Cell Assay28 (SCA), which is a 
highly sensitive and quantitative assay for the presence of RML prions. 
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Western Blotting   
Samples were analyzed by electrophoresis and immunoblotting following Proteinase K 
digestion (200 μg/ml final protease concentration) as described previously 27,29. Blots 
were blocked in PBS containing 0.05 % (v/v) Tween-20 (PBST) and 5 % (w/v) non-fat 
milk powder and probed with a biotinylated anti-PrP monoclonal antibody ICSM 18 (D-
Gen Ltd, London, UK) at 200 ng/ml final antibody concentration in PBST. Blots were 
developed using a Streptavidin-Alkyline Phosphatase conjugate (Dako, Denmark) diluted 
1:10,000 in PBST and chemiluminescent substrate CDP-Star (Tropix Inc, Bedford, MA, 
USA).  Blots were visualized on Biomax MR film (Kodak; Anachem Ltd, UK) as 
described 27 and signal intensity of bands was quantified using Imagequant software 
(Molecular Dynamics). 
 
Protein Misfolding Cyclic Amplification 
Protein Misfolding Cyclic Amplification (PMCA) was performed as described previously 
16.  Briefly, 10% (w/v) PMCA substrate homogenates were prepared from Tg20 mice 
brains which had been perfused with PBS containing 5 mM EDTA at the time of death.  
Brains were homogenised in cold conversion buffer (PBS containing 150mM NaCl, 1.0% 
Triton X-100, 4mM EDTA and Complete Protease Inhibitor Mixture (Roche Applied 
Biosciences)).  Substrate homogenates were clarified by centrifugation at 1000 g for 45 
seconds and then stored at -70°C without freeze-thawing until required.  RML infected 
homogenate was diluted into 100 µl of substrate homogenate in 0.2 ml PCR tubes and 40 
µl retained as minus PMCA controls.  Samples were subjected to 140 cycles of PMCA 
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consisting of a 20 second pulse of sonication at 75% power output using a Misonix 
S3000  sonicator with a microplate horn (Misonix, Farmingdale, USA) followed by 
incubation for 30 minutes at 35oC.  In serial PMCA experiments, samples were subjected 
to successive rounds of 140 PMCA cycles followed by 1:10 dilution into fresh substrate 
homogenate. 
 
For PMCA of RML time course and normal blood samples, 1µl of pooled whole blood 
from 140 day post-infection and uninfected animals was diluted 1:100 into PMCA 
substrate homogenate.  After mixing, 40 µl was removed and stored at -70°C as a PMCA 
minus control.  Samples were subjected to serial PMCA as described above.  All samples 
were analysed by PK digestion (200 µg/ml final protease concentration for 60 minutes at 
37°C) and Western blotting. 
 
 10
Results 
 
Serial PMCA of RML infected brain homogenates 
To determine the extent of amplification within our PMCA experiments we performed 
serial PMCA on RML infected CD1 brain homogenates diluted into transgenic Tg2023 
substrate homogenate.  RML homogenate was diluted 400 fold and subjected to 140 
cycles of PMCA.  Further dilutions (10, 100 and 200 fold) were performed into fresh 
substrate and two subsequent rounds of sPMCA were undertaken (Figure 1).  In all cases 
PrPSc was amplified efficiently, with a 20 to 40 fold increase in PK resistant material at 
each sPMCA step when compared to the PK resistant PrP in samples which were not 
subjected to PMCA.  Overall the total amplification achieved was > 16000 fold at the 
highest dilution, confirming our PMCA system using transgenic murine brain 
homogenate as the substrate is an efficient means of amplifying mouse PrPRES. 
 
Amplification of PrPSc spiked into normal whole blood 
To establish the efficacy of our Tg20 system to amplify PrPRES out of whole blood, we 
prepared samples containing RML homogenate diluted into either normal CD1 
homogenate or whole blood.  These were then used to seed Tg20 PMCA substrate 
homogenates (1 µl into 100 µl) giving a final dilution of seed RML of 400 and 800 fold 
(Figure 2).  Amplification of PrPRES spiked into whole blood was consistently obtained in 
all samples over a single PMCA experiment.  However, there was a reduction of 
amplification capability of approximately 50% due to the inhibitory nature of whole 
blood, which could not be overcome by further optimisation. 
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Discrimination between whole bloods from normal and pre-clinical RML infected 
animals 
A time course of RML infection after intracerebral inoculation previously performed was 
monitored by western blot detection for PrPSc accumulation in the brain and associated 
infectivity by cell-culture assay (SCA)28,30. Brains from 20 animals at each time point 
were homogenised and analysed independently with PK resistant PrPSc first detected in 
brain tissue at 60 days post-infection (pi) (9 out of 20) and gave uniformly positive 
results 100-120 days pi (Figure 3).  However, infectivity measured by SCA was not 
observed in brain tissue until 100 days pi, reaching a maximum at 140 days pi with a 
mean titre of 2.6 x 108 TCLD50 units while animals were still symptom free.  Clinical 
onset was at 148 days and all animals were sacrificed at this time point.   
 
Blood samples were collected and pooled from animals at all time points.  Whole blood 
from pre-symptomatic animals 140 days post-infection was used to seed serial PMCA 
reactions.  Normal uninfected blood was used as a negative control and RML brain 
homogenate spiked into whole blood used as a positive control of amplification.  Great 
care was taken when handling the controls to eliminate the likelihood of contamination to 
the blood spiked samples.  For that reason, control samples were handled using clean 
gloves and pipettes separately from the experimental samples.  By sPMCA round 3, 
PrPRES could be detected in 1 out 3 reactions spiked with blood obtained from infected 
animals at 140 days post infection.  After a further cycle of sPMCA, PrPRES was observed 
in all three infected blood reactions (Figure 4), whereas no detectible PrPRES resulted 
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from sPMCA of the normal blood controls at either round 3 or 4, indicating that 
spontaneous generation of PrPRES is unlikely to have occurred during the period of the 
experiment19,24. 
 
Reliable amplification of PrPRES could only be achieved from whole blood obtained 140 
days post infection and later. This finding appears to correlate with the sharp rise in 
infectious titre in the brains of affected animals (Figure 3) which occurs between 100 and 
140 days post infection before plateauing prior to the onset of a clinical syndrome. 
 13
Discussion 
Here we detail the first amplification of PrPRES from whole blood and the clinical 
discrimination between normal and prion infected pre-symptomatic animal bloods.  
Although PrPRES has been successfully amplified from blood leukocyte preparations in 
rodents and sheep17-19 by PMCA, buffy coat is unlikely to be a plausible analyte for a 
blood screening assay that can be utilised on a large scale due to the prohibitive time and 
complexity for preparation. Whole blood represents a more practical material for a blood 
test as well as being guaranteed to contain the entirety of PrP and prion infectivity in the 
sample. These results suggest that with carefully optimisation for human PMCA it should 
be possible to distinguish between normal blood and that from vCJD patients.   
 
Despite these promising results, PMCA still remains a technically challenging procedure.  
As well as obvious problems such the time consuming nature of serial PMCA and the 
possibility of de novo generation of PrPRES 19,24, choosing the ideal substrate for testing is 
crucial.  In our experiments there is a significant inhibition of amplification (~50%) in the 
presence of whole blood (Figure 2).  Careful study of the effect on amplification 
efficiency by individual blood components may reveal and allow the exclusion of the 
inhibitory species.  Removal of any such species would greatly increase the sensitivity of 
PMCA as a method of detecting PrPSc in infected blood samples. 
 
Another issue of concern limiting the use of PMCA in its current state is the adaptation of 
the technique to different species.  Finding a suitable substrate for amplification of human 
PrPSc remains a problem.  It is unlikely that there will be a readily available supply of 
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normal human brains in the quantities necessary for large scale screening.  Therefore 
alternative amplification substrates must be investigated.  The use of human platelets has 
recently been shown to be effective in the amplification of human PrPSc 31, although there 
is concern over their widespread usefulness due to codon 129 compatibility problems 
between substrate and seed.  Transgenic animals that express the human prion protein 
have also been suggested as a conceivable source of PMCA substrate.  The simplest and 
most easily attainable substrate for amplification is recombinant prion protein, which can 
be cheaply produced in large quantities.  Recent reports show the promise of using 
recombinant protein as a substrate for the diagnostic distinction between normal and 
prion infected cerebrospinal fluid13,32.  However, unlike PMCA these reactions do not 
result in the replication of prion infectivity, questioning their fidelity and they may be 
significantly more susceptible to false positive results from other amyloidoses.  
 
The detection of PrPSc in blood is considerably more challenging than other tissues with 
as little as 10 infectious units present in 1ml of whole blood. In order to achieve the high 
levels of sensitivity required a blood-based CJD diagnostic assay will need to exploit the 
unique ability of prions to replicate and incorporate an in vitro amplification step in the 
methodology. However, amplification alone does not provide a solution to blood based 
diagnosis due in part to the low abundance of PrPSc requiring large volumes of blood to 
be sampled to obtain certainty that at low titres during pre-clinical stages of infection a 
prion particle is certain to be present. In addition the experimental complexities and time 
scales of amplifying from low titre analytes would preclude the use of amplification 
alone as a screening assay. It is likely that a combination of enrichment, amplification 
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and high sensitivity detection will be required to reduce the time scales involved and 
robustly provide the very high levels of sensitivity and specificity required of a blood 
screening assay. 
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Figure Legends 
 
Figure 1.  Serial PMCA of PrPRES using transgenic Tg 20 substrate homogenate 
As a proof of concept, 10% (w/v) RML infected brain homogenate was diluted 1:400 into 
PMCA substrate containing brain homogenate from uninfected CD1 mice and subjected 
to 140 rounds of amplification (sPMCA #1). Samples subjected to PMCA contained 
more than 40 times thte level of PrPRES in unamplified controls. Amplified material was 
then diluted into fresh substrate and PMCA was repeated for another 140 cycles (sPMCA 
#2 and #3). Each serial cycle of dilution and amplification yielded levels of PrPRES in the 
region of 20-40 fold higher than control dilutions which were not subjected to PMCA, 
giving a total amplification of ~16,000x (40x20x20) from the original RML at the highest 
dilutions. 
 
Figure 2. Amplification of PrPRES spiked into whole blood 
RML infected brain homogenate was diluted (1:4 and 1:8) into either normal CD1 brain 
homogenate or uninfected whole blood.  1 μl of each dilution was added to 100 μl  Tg 20 
substrate homogenate and subjected to 140 cycle of PMCA.  PrPRES was amplified to 
detectable levels from whole blood as well as normal brain.  The efficiency of 
amplification was reduced by ~50% due to the inhibitory nature of whole blood, an 
inhibition that could not be overcome by further optimisation of reaction conditions. 
 
Figure 3.  RML infection time course in CD1 mice 
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A large cohort of CD-1 mice were inoculated i.c. with 30μl of a 1% (w/v) RML-infected 
brain homogenate. Groups of 20 mice were culled at 0, 20, 40, 60, 80, 100, 120, 140 days 
post-infection and succumbed to clinical disease at 148 days pi. Brain were homogenised 
and analysed independently for the presence of PrPSc by western blotting and infectivity 
quantified by Scrapie Cell Assay. Western blotting of brain homogenates gave uniformly 
positive results from 120 days post infection and mean levels of infectivity reached a 
maximum at around 140 days. Blood from 20 mice at each time point was pooled to 
provide a single sample per time point. 
 
Figure 4.  Differentiation between normal whole blood and blood from pre-
symptomatic RML infected mice 
Whole blood from infected RML CD-1 mice collected 140 days post infection and 
normal, uninfected whole blood from CD1 mice were diluted 1:100 into PMCA substrate 
homogenate. Whole blood spiked with RML (1:10) was also diluted 1:100 into PMCA 
substrate positive control for amplification. Serial PMCA was performed on all samples. 
After 4 consecutive rounds of sPMCA, amplification of PrPRES could be detected in all of 
the RML infected blood samples. No PrPRES was detectable in the normal uninfected 
blood samples. 
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